Because guidelines recommend angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for kidney protection for chronic kidney disease and/or diabetes, as well as for cardiovascular prevention for diabetes and atherosclerotic cardiovascular disease,37,38,39 we would expect that patients with multiple comorbidities would be taking multiple, but lower-dose, medications to gain benefits for these comorbid conditions. The gene discussed is ACE; the disease is chronic kidney disease.